EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Alport Syndrome, X-Linked
Alport Syndrome, Autosomal Recessive
Interventions
DRUG:
Exaluren
Sponsor
Eloxx Pharmaceuticals, Inc.